A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial
Open Access
- 8 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 32 (9) , 1915-1924
Abstract
Can increasing the duration of LH-exposure with a second dose of kisspeptin-54 improve oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS)? A second dose of kisspeptin-54 at 10 h following the first improves oocyte yield in women at high risk of OHSS. Kisspeptin acts at the hypothalamus to stimulate the release of an endogenous pool of GnRH from the hypothalamus. We have previously reported that a single dose of kisspeptin-54 results in an LH-surge of ~12–14 h duration, which safely triggers oocyte maturation in women at high risk of OHSS. Phase-2 randomized placebo-controlled trial of 62 women at high risk of OHSS recruited between August 2015 and May 2016. Following controlled ovarian stimulation, all patients (n = 62) received a subcutaneous injection of kisspeptin-54 (9.6 nmol/kg) 36 h prior to oocyte retrieval. Patients were randomized 1:1 to receive either a second dose of kisspeptin-54 (D; Double, n = 31), or saline (S; Single, n = 31) 10 h thereafter. Patients, embryologists, and IVF clinicians remained blinded to the dosing allocation. Study participants: Sixty-two women aged 18–34 years at high risk of OHSS (antral follicle count ≥23 or anti-Mullerian hormone level ≥40 pmol/L). Setting: Single centre study carried out at Hammersmith Hospital IVF unit, London, UK. Primary outcome: Proportion of patients achieving an oocyte yield (percentage of mature oocytes retrieved from follicles ≥14 mm on morning of first kisspeptin-54 trigger administration) of at least 60%. Secondary outcomes: Reproductive hormone levels, implantation rate and OHSS occurrence. A second dose of kisspeptin-54 at 10 h following the first induced further LH-secretion at 4 h after administration. A higher proportion of patients achieved an oocyte yield ≥60% following a second dose of kisspeptin-54 (Single: 14/31, 45%, Double: 21/31, 71%; absolute difference +26%, CI 2–50%, P = 0.042). Patients receiving two doses of kisspeptin-54 had a variable LH-response following the second kisspeptin dose, which appeared to be dependent on the LH-response following the first kisspeptin injection. Patients who had a lower LH-rise following the first dose of kisspeptin had a more substantial ‘rescue’ LH-response following the second dose of kisspeptin. The variable LH-response following the second dose of kisspeptin resulted in a greater proportion of patients achieving an oocyte yield ≥60%, but without also increasing the frequency of ovarian over-response and moderate OHSS (Single: 1/31, 3.2%, Double: 0/31, 0%). Further studies are warranted to directly compare kisspeptin-54 to more established triggers of oocyte maturation. Triggering final oocyte maturation with kisspeptin is a novel therapeutic option to enable the use of fresh embryo transfer even in the woman at high risk of OHSS. The study was designed, conducted, analysed and reported entirely by the authors. The Medical Research Council (MRC), Wellcome Trust & National Institute of Health Research (NIHR) provided research funding to carry out the studies. There are no competing interests to declare. Clinicaltrial.gov identifier NCT01667406 8 August 2012. 10 August 2015.Keywords
Funding Information
- Medical Research Council (MRC)
- Biotechnology and Bioscience Research Council (BBSRC)
- National Institute for Health Research (NIHR)
- NIHR/WellcomeTrust Imperial Clinical Research Facility and Imperial Biomedical Research Centre
- NHS
- NIHR Biomedical Research Centre funding scheme
- National Institute of Health Research (NIHR) Clinical Lectureships
- NIHR Research Professorship
- NIHR Academic Clinical Fellowship and Imperial College Healthcare NHS trust Charity Fellowship
- MRC clinical training fellowship
This publication has 42 references indexed in Scilit:
- GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patientsHuman Reproduction, 2013
- Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCGHuman Reproduction, 2013
- Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 womenFertility and Sterility, 2012
- Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control studyFertility and Sterility, 2011
- Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles2011
- Kisspeptin-10, a KISS1-Derived Decapeptide, Inhibits Tumor Angiogenesis by Suppressing Sp1-Mediated VEGF Expression and FAK/Rho GTPase ActivationCancer Research, 2009
- Kisspeptin–GPR54 Signaling Is Essential for Preovulatory Gonadotropin-Releasing Hormone Neuron Activation and the Luteinizing Hormone SurgeThe Journal of Neuroscience, 2008
- Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cyclesFertility and Sterility, 2006
- Peripheral administration of metastin induces marked gonadotropin release and ovulation in the ratBiochemical and Biophysical Research Communications, 2004
- Ovarian Hyperstimulation SyndromeObstetrical & Gynecological Survey, 1989